TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03293862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prophylactic polypropilene mesh
Description: Placement of onlay polypropilene prophylactic mesh after midline fascial closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midline Fascial Closure
Description: midline fascial closure using uninterrupted PDS 0 suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline Fascial Closure
Description: midline fascial closure using uninterrupted PDS 0 suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vacuum drainage system
Description: Placement of a subcutaneous vacuum drainage system
Study: NCT03412838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: graft surgery
Description: A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: graft surgery
Description: A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
Study: NCT01400100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial application of Octreotide
Description: 500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile NaCl (sodium chloride) 0,9% solution
Description: a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
Study: NCT04609293

Intervention type: COMBINATION_PRODUCT
Intervention: camrelizumab+apatinib+hyperfractionated radiotherapy
Description: Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
Study: NCT01072799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H1N1 2009 Influenza VLP Vaccine
Description: Two doses (Day 1 \& Day 22); 0.5mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H1N1 2009 Influenza VLP Vaccine
Description: Two doses (Day 1 \& Day 22); 0.5mL
Study: NCT00536588

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SCH 721015 with SCH 209702
Description: Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
Study: NCT02251509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Study: NCT01910831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DerMend Moisturizing Bruise Formula
Description: DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-active placebo control
Description: Non-active placebo control
Study: NCT00288769

Intervention type: DRUG
Group type: OTHER
Intervention: daily sublingual tablets Vitamin B12 1000 mcg versus placebo
Study: NCT04747184

Intervention type: OTHER
Intervention: DNA extraction and 16S rRNA sequencing
Description: DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.

Intervention type: OTHER
Intervention: DNA extraction and 16S rRNA sequencing
Description: DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
Study: NCT02583308

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tubes not allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tubes allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
Study: NCT02527330

Intervention type: OTHER
Intervention: MR T2* imaging
Description: Cardiac magnetic resonance imaging with T2\* imaging

Intervention type: OTHER
Intervention: MR T2* imaging
Description: Cardiac magnetic resonance imaging with T2\* imaging

Intervention type: OTHER
Intervention: MR T2* imaging
Description: Cardiac magnetic resonance imaging with T2\* imaging
Study: NCT01195155

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LC n-3 PUFA (fish oil) Supplement
Description: 4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LC n-3 PUFA (fish oil) Supplement
Description: 4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: LC n-3 PUFA (fish oil) Supplement
Description: 4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
Study: NCT02007161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac potassium 50 mg
Description: Diclofenac potassium 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac potassium 50 mg
Description: Diclofenac potassium 50 mg
Study: NCT01117662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous application of placebo (NaCl 0,9 %) matching active treatment
Study: NCT03527979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: IVF/ICSI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: IVF/ICSI
Study: NCT00569075

Intervention type: OTHER
Intervention: collection of gingival crevicular fluid
Description: GCF samples will be collected at 3 month intervals

Intervention type: OTHER
Intervention: collection of gingival crevicular fluid
Description: GCF samples will be collected at 3 month intervals
Study: NCT02019173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Boot Camp Balance Training
Description: Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
Study: NCT04179084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: 5mg qd, 2weeks on, 1week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg q3w
Study: NCT02150993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + Emtricitabine or Lamivudine + Zidovudine
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + Emtricitabine or Lamivudine + Raltegravir
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
Study: NCT03221335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided RFA
Description: All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
Study: NCT02320552

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT02312128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: DASH Score, PRWE Score, Mayo Wrist Score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: DASH Score, PRWE Score, Mayo Wrist Score

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X- Ray
Description: X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X- Ray
Description: X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
Study: NCT01027767

Intervention type: DEVICE
Intervention: Molecular Breast Imaging
Description: Molecular Breast Imaging

Intervention type: DEVICE
Intervention: Molecular Breast Imaging
Description: Molecular Breast Imaging
Study: NCT04315701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study: NCT02312128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grip Strength
Description: Grip strength measurement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grip Strength
Description: Grip strength measurement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAS Score
Description: Measurement pain according to the visual analogue scale (VAS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAS Score
Description: Measurement pain according to the visual analogue scale (VAS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of Motion measurement
Description: Angle measurement of the active range of motion in the wrist
Study: NCT04315701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT02046733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
Study: NCT03606629

Intervention type: DEVICE
Intervention: Endoprosthesis implantation
Description: Endoprosthesis implantation by Percutaneous Angioplasty
Study: NCT02487290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aneufix ACP-T5
Description: The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
Study: NCT02206685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
Study: NCT02312128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of Motion measurement
Description: Angle measurement of the active range of motion in the wrist
Study: NCT02206685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
Study: NCT04442672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute compartment syndrome model of health volunteer
Description: the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: surrounding the cuff but not inflate it.
Study: NCT00072475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Description: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
Study: NCT02649114

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy
Study: NCT03743519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: 30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in taste and colour to the Cherry juice, but with no anthocyanin content
Study: NCT00597974

Intervention type: PROCEDURE
Intervention: Angioplasty
Description: (non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
Study: NCT03456076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectnib
Description: Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
Study: NCT00597974

Intervention type: PROCEDURE
Intervention: Angioplasty
Description: (non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty

Intervention type: DEVICE
Intervention: Stent
Description: (non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)

Intervention type: DEVICE
Intervention: Stent
Description: (non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)

Intervention type: OTHER
Intervention: Neurological and neuropsychological evaluations
Description: Clinical examinations consisting of a neurological and neuropsychological evaluation

Intervention type: OTHER
Intervention: Neurological and neuropsychological evaluations
Description: Clinical examinations consisting of a neurological and neuropsychological evaluation
Study: NCT04415151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be administered.
Study: NCT02167347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention
Description: This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
Study: NCT06437457

Intervention type: RADIATION
Intervention: ceus
Description: MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.

Intervention type: RADIATION
Intervention: ceus
Description: MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.
Study: NCT00597974

Intervention type: PROCEDURE
Intervention: Angiography
Description: (non-experimental) Coronary angiography

Intervention type: PROCEDURE
Intervention: Angiography
Description: (non-experimental) Coronary angiography
Study: NCT00731016

Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid, pravastatin
Description: Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid
Study: NCT05235243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online therapeutic intervention for maladaptive daydreaming based on mindfulness and self-monitoring
Description: An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online therapeutic intervention for maladaptive daydreaming based on mindfulness
Description: An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
Study: NCT00886912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypoxia
Description: training in simulated altitude in a hypoxic chamber (normobaric hypoxia)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normoxia
Description: training under normoxic conditions
Study: NCT00662688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daltéparine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy at the investigator's discretion